RADNOR, Pa. (AP) — RADNOR, Pa. (AP) — Marinus Pharmaceuticals Inc. (MRNS) on Tuesday reported a loss of $41.8 million in its fourth quarter.

The Radnor, Pennsylvania-based company said it had a loss of 74 cents per share.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share.

The epilepsy drug developer posted revenue of $7.2 million in the period, also falling short of Street forecasts. Five analysts surveyed by Zacks expected $7.8 million.

For the year, the company reported a loss of $141.4 million, or $2.63 per share. Revenue was reported as $31 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRNS at https://www.zacks.com/ap/MRNS

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News